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Objective—To examine the distribution of birth weight in children with NAFLD compared with 
the general U.S. population and the relationship between birth weight and severity of NAFLD.
Study design—A multi-center, cross-sectional study of children with biopsy-proven NAFLD 
enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network Database. Birth weights 
were categorized as low birth weight (LBW), normal birth weight (NBW), or high birth weight 
(HBW) and compared with distribution of birth weights in the general US population. The severity 
of liver histology was assessed by birth weight category.
Results—Children with NAFLD (n=538) had overrepresentation of both LBW and HBW 
compared with the general US population (LBW 9.3%, NBW 75.8%, HBW 14.9% vs. LBW 
6.1%, NBW 83.5%, HBW 10.5%; p<0.0001). Children with HBW had significantly greater odds 
of having more severe steatosis (OR 1.82, 95% CI 1.15–2.88) and NASH (OR 2.03, 95% CI 1.21–
3.40) than children with NBW. Additionally, children with NAFLD and LBW had significantly 
greater odds of having advanced fibrosis (OR 2.23; 95% CI 1.08–4.62).
Conclusion—Birth weight involves maternal and in utero factors which may have long-lasting 
consequences. Children with both LBW and HBW may be at increased risk for developing 
NAFLD. Among children with NAFLD, those with LBW or HBW appear to be at increased risk 
for more severe disease.
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Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease 
in the pediatric population. (1, 2) NAFLD encompasses a broad spectrum of disease severity 
ranging from isolated steatosis in its mildest form, to nonalcoholic steatohepatitis (NASH) 
accompanied by inflammation and hepatocellular injury with or without fibrosis in its more 
severe form. (3) NAFLD is typically discovered in early adolescence with the average age of 
diagnosis being 12 years of age. (3) Children have varying degrees of disease severity at the 
time of diagnosis, with 20–30% of those with NAFLD having NASH, and 10–15% of those 
with NAFLD having advanced fibrosis. (4, 5) However, exposure variables that are 
meaningfully associated with the onset of the pathologic process or the range of outcome 
severity in children with NAFLD are underexplored.
The perinatal period is a critical time in development that may have long lasting influences 
on the development of NAFLD. From animal studies, we have learned that both the state of 
under-nutrition(6) and over-nutrition in utero(7) have the capacity to program the developing 
fetus in terms of lipid and glucose metabolism, thereby altering risk for development of a 
range of cardiometabolic diseases in later life. Birth weight is a concrete measure of this 
fetal adaptation and programming during pregnancy, and has been examined as a risk factor 
for conditions associated with NAFLD in humans, such as type 2 diabetes mellitus(8) and 
hypertension. (9) The presence of hepatic steatosis in the neonatal period has been 
demonstrated via imaging and histopathology in several studies supporting the concept that 
the potential for NAFLD is influenced by the intrauterine environment. (10–12)
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Data in both children and adults suggest that low birth weight is associated with a greater 
risk for development of NAFLD. (13, 14) There is no data on the relationship between high 
birth weight and NAFLD. We hypothesized that birth weights outside of the normal range, 
either low or high, influence the risk for NAFLD. Therefore, the study aims were to evaluate 
the distribution of birth weight in children with NAFLD compared with the general U.S. 
population and the association of low birth weight and high birth weight with the severity of 
NAFLD as determined by liver histology.
METHODS
Data were obtained from children who were enrolled in the Database of the National 
Institute of Diabetes and Digestive and Kidney Diseases NASH Clinical Research Network 
(NASH CRN). Participants in this study were selected from those enrolled in NASH CRN 
studies at 13 participating clinical centers between 2004 and 2012. (15, 16) Inclusion criteria 
for this analysis were age less than 21 years at registration, having a parent-reported birth 
weight, and having NAFLD. The decision for inclusion of subjects was based on the 
prevailing National Institutes of Health definition of child (under 21 years of age) at the time 
this study was designed and implemented. A diagnosis of NAFLD was based on liver 
histology with ≥ 5% of hepatocytes containing macrovesicular fat and exclusion of other 
causes of chronic liver disease by clinical history, laboratory studies, and histology. Children 
were excluded if they had implausible birth weights (i.e. numeric value representing height 
recorded instead of weight) or if they had very low birth weight (< 1,500 grams; VLBW) 
because the children with VLBW were excluded from the 1977 National Center for Health 
Statistics and 2000 Center for Disease Control and Prevention growth charts.
The Institutional Review Board at each participating center approved this study. Written 
informed consent for all participants was obtained from the participant (if age ≥18 years of 
age) or from a parent or guardian, and written informed assent was obtained from all 
children 8 years or older prior to participation.
Phenotyping of cohort
Demographic data on study participants were obtained via a structured interview. Weight 
and height were measured to the nearest 0.1kg and 0.1 cm respectively. Weight, height, and 
waist measurements were performed in duplicate while wearing light clothing without 
shoes. BMI was calculated as weight (kg) divided by height (m) squared. BMI percentile 
was determined according to age and sex based on data from the Centers for Disease Control 
and Prevention. To compare BMI among different ages and in both boys and girls, the BMI 
Z-score was calculated.
Participants fasted overnight for 12 hours before phlebotomy via venipuncture. Each clinical 
center performed reported laboratory assays on site to include the following tests: glucose, 
insulin, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density 
lipoprotein (LDL) cholesterol, triglycerides, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and gamma glutamyltransferase (GGT).
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Liver Histology
A diagnosis of NAFLD was based on liver histology with ≥ 5% of hepatocytes containing 
macrovesicular fat and exclusion of other causes of chronic liver disease by clinical history, 
laboratory studies, and histology. Liver biopsy specimens were stained with hematoxylin-
eosin and Masson’s trichrome stain and centrally reviewed by the Pathology Committee of 
the NASH CRN according to the NASH CRN scoring system. (17) Members of the 
Pathology Committee were blinded to all demographic and clinical data. Biopsies were 
scored for the degree of steatosis present in hepatocytes as follows: grade 0, < 5% steatosis; 
grade 1, 5 to 33%; grade 2, 34 to 66%; and grade 3, > 66%. Liver biopsies were diagnosed 
as nonalcoholic steatohepatitis (NASH), borderline NASH, “NAFLD, not NASH,” or not 
NAFLD based on the aggregate presence and degree of the individual features of NAFLD. A 
typical set of minimum criteria to diagnose NASH would include > 5% macrovesicular 
steatosis, lobular inflammation and hepatocyte injury as manifest by ballooning 
degeneration. Cases determined to be NAFLD not NASH showed > 5% steatosis with no or 
minimal inflammation. Cases diagnosed as “Borderline NASH” had steatosis and 
inflammation but equivocal or no ballooning degeneration with or without a fibrosis pattern 
typical of NASH. Also included in the “Borderline NASH” category (type 2) were cases 
with portal inflammation and/or fibrosis, with a zone 1 or panacinar distribution of steatosis, 
that is, the pattern of fatty liver disease common in children. (1, 18) This assignment of 
NASH, borderline NASH, or NAFLD was made as a consensus agreement of the NASH 
CRN pathology group at the time of central review of cases as per protocol.
Exposure Variable: Birth Weight Category
Parents were asked for the participating child’s birth weight. Birth weights were categorized 
as low birth weight (1,500 to 2,499 grams; LBW), normal birth weight (2,500 to 3,999 
grams; NBW), or high birth weight (≥4,000 grams; HBW).
Data Analysis Plan
Descriptive statistics used to compare characteristics in children with LBW, NBW, or HBW 
included means, standard deviations, medians, ranges, frequencies, and percentages. 
Analysis of variance and Tukey’s test for pairwise comparisons were used to obtain p-values 
for continuous variables. Chi-square and Fisher exact tests were used to obtain p-values for 
categorical variables. Severity of NAFLD was determined using three different histologic 
measures: grade of steatosis, the presence of NASH, and the presence of advanced fibrosis. 
For the ordinal outcome of steatosis grade, ordinal logistic regression was used. For the 
dichotomous outcomes of NASH diagnosis and advanced fibrosis, logistic regression models 
were constructed. Covariates were assessed as confounders by determining if they resulted 
in a greater than a ten percent change in the main exposure of interest. Age, sex, race/
ethnicity, and BMI were found to be confounders in at least one of the outcome models and 
were included in all final multivariate models.
The distribution of the birth weight categories of this study cohort was compared with the 
distribution of the birth weight categories in the general US population for 1995 (median 
year of birth for study sample). (19) A one-sample Chi-square test was used to determine the 
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p-value. SAS version 9.3 (SAS Institute) was used to perform all analyses. Statistical 
significance was defined as p ≤0.05.
RESULTS
There were 605 children enrolled in the NASH CRN for initial consideration for study 
participation, and of these, 34 subjects were excluded for missing birth weight data, 17 
subjects were excluded because they did not have biopsy-confirmed NAFLD, 12 subjects 
were excluded because reported birth weight was implausible, and four subjects were 
excluded because they were VLBW. The remaining 538 children were included in this 
analysis. The demographic and clinical measures are shown in Table I. The mean age of the 
participants was 13 ± 3 years. The median BMI of participants was 32.0 Kg/m2, with a 
median BMI z-score of 2.33. The majority of participants (71%) were boys. Among children 
with NAFLD, 9.3% (50 of 538) had LBW, 75.8% (408 of 538) had NBW, and 14.9% (80 of 
538) had HBW. Definite NASH was present in 26.6%.
Distribution of Birth Weight in Children with NAFLD Compared with the General U.S. 
Population
The distribution of birth weight categories was significantly different for children with 
NAFLD compared with the general US population, such that both low and high birth 
weights were overrepresented, (LBW 9.3% vs. 6.1%, NBW 75.8% vs. 83.5%, HBW 14.9% 
vs. 10.5%; p<0.0001).
Relationship Between Birth Weight and Clinical Characteristics of Children with NAFLD
Among children with NAFLD, there was no significant difference by age, sex, or ethnicity 
between children with LBW, NBW, or HBW. (Table I.) However, at the time of diagnosis of 
NAFLD, there was a significant (p<0.001) difference in height and weight by birth weight 
category. At the time of enrollment in the NASH CRN, at a mean age of 13 years, children 
in the HBW group were significantly heavier (90 kg vs. 83 kg) and taller (166 cm vs. 159 
cm) than children in the NBW group, and children in the LBW group were significantly 
shorter (157 cm vs. 166 cm) and lighter (71 kg vs. 90 kg) than children in the HBW group. 
Similarly, median BMI (HBW 33.3 Kg/m2, NBW 32.0 Kg/m2, LBW 30.4 Kg/m2, p =0.02) 
and BMI z-scores (HBW 2.37, NBW 2.33, LBW 2.31, p=0.05) were significantly higher in 
HBW compared with NBW and LBW groups. There was no significant difference in ALT, 
AST, GGT, total cholesterol or triglycerides by birth weight group.
The Relationship Between Birth Weight and Severity of NAFLD
Steatosis Grade—The distribution of steatosis grade by birth weight category is shown in 
Table II. Notably, 51.3% (41 of 80) of children with HBW had severe steatosis. After 
controlling for age, sex, height, weight, race and ethnicity, children with HBW had 1.82 
times the odds of having more severe steatosis than children with NBW (OR 1.82, 95% CI 
1.15–2.88, p= 0.01). The distribution of steatosis did not differ between children with LBW 
compared with children with NBW. (Table III)
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NASH—As shown in Table II, the presence of steatohepatitis varied significantly by birth 
weight category. NASH was present in 30.0% (15 of 50) of those with LBW, 23.5% (96 of 
408) of those with NBW, and 40.0% (32 of 80) of those with HBW, (p< 0.01). After 
controlling for age, sex, height, weight, race and ethnicity, among children with NAFLD, the 
odds of having NASH was 2.03 times higher in those with HBW compared with children 
with NBW (OR 2.03, 95% CI 1.21–3.40, p<0.01). The diagnosis of NASH did not differ 
between children with LBW compared with children with NBW. (Table III)
Advanced Fibrosis—Advanced fibrosis was present in 24.0% (12 of 50) of those with 
LBW, 12.8% (52 of 406) of those with NBW, and 16.3% (13 of 80) of those with HBW, (p = 
0.09). After controlling for age, sex, height, weight, race and ethnicity, children with LBW 
had 2.23 times greater odds of having advanced fibrosis than children with NBW (OR 2.23; 
95% CI 1.08–4.62, p = 0.03). Advanced fibrosis did not differ between children with HBW 
compared with children with NBW. (Table III)
DISCUSSION
We studied birth weight in a large multi-center cohort of children with NAFLD from 
pediatric centers across the United States. Children with NAFLD had a significantly 
different distribution of birth weights compared with the general US population, with 
overrepresentation of both low and high birth weight. Children with HBW had significantly 
greater odds of having more severe steatosis and NASH than children with NBW. In 
contrast, children with LBW had twice the odds of having advanced fibrosis than children 
with NBW.
There has been an increasing awareness of the potential for perinatal factors to have lifelong 
ramifications for future morbidity and mortality. (20), (21) Studies primarily focused on the 
relationship between LBW with cardiovascular disease(22) and type 2 diabetes (23) have 
found an inverse relationship between birth weight and future disease risk. A study 
investigating the relationship between birth weight and NAFLD in the pediatric population 
previously, showed a fourfold increased prevalence of children born small for gestational age 
in those with NAFLD compared with a control population.(13) Overall, fewer studies have 
focused on HBW and long-term health, and results have been less consistent. (24) However, 
the frequency of children born with HBW has greatly increased recently (25) in parallel with 
the epidemic of obesity, and thus implications of HBW for future health have not been fully 
characterized. This study demonstrated a bimodal distribution of risk for NAFLD related to 
birth weight. Although both low and high birth weight were associated with increased risk 
for NAFLD, distinctive pathophysiologic mechanisms are likely involved, supported by our 
finding of disparate hepatic phenotypic tendencies observed between birth weight categories.
In children with NAFLD, LBW was associated with a higher risk of advanced fibrosis. This 
finding is consistent with data from a study by Andersen and Osler that demonstrated a 
strong and graded inverse relationship between small birth size and death from cirrhosis in 
young adult men. (26) A potential explanation was provided in a guinea pig model that 
showed that LBW was associated with changes in hepatic pro-fibrotic genes and liver 
fibrosis independent of obesity. (27) As fibrosis is the most important measure with respect 
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to liver-related morbidity and mortality, a better understanding of these early life events that 
influence fibrosis potential is essential to reduce negative hepatic outcomes.
Unexpectedly, children with NAFLD who were born with HBW remained larger by all 
measures at a mean age of 13 years than children with NAFLD who were born with NBW or 
LBW, thus reinforcing that the risk for more severe obesity is associated with HBW. (28–30) 
In keeping with more severe obesity, children with HBW had greater severity of steatosis. 
One possible explanation for this finding is that children with HBW develop steatosis earlier 
than other children. Although obtaining maternal health information was beyond the scope 
of this investigation, prior studies have shown that mothers with elevated BMI and diabetes 
are prone to have children born large for gestational age, and that hepatic steatosis is more 
likely to be present at birth in these infants. (10, 11) Data from animal studies have shown 
that a maternal high fat diet can produce offspring with HBW and neonatal hepatic steatosis 
that persists with maturation. (31, 32) Importantly, in our study, children with HBW not only 
had more severe steatosis, but also had greater odds of having NASH. Studies in animal 
models have also shown that a maternal high fat diet can cause life long impairment of 
hepatic mitochondrial metabolism in the offspring that is associated with steatohepatitis. 
(33) Thus, HBW may be an early marker for imprinting that predisposes a child to both 
NAFLD itself as well as for more severe disease in the form of steatohepatitis.
This study was performed by the NASH CRN, which has diverse geographic representation 
of children with accurate and rigorously characterized NAFLD. A limitation was that some 
factors with the potential to influence the relationship between birth weight and NAFLD 
were not fully captured. Examples of such factors include gestational age at birth, maternal 
weight and health status during pregnancy, and post-natal factors such as breastfeeding, 
antibiotic administration, and post-natal growth trajectories. Although we did exclude 
children with VLBW, we did not have the gestational age at birth, and thus may have 
included children born preterm. Moreover, we could not distinguish LBW from small for 
gestational age. Additionally, original birth records of weight were not available and thus, 
the potential for error exists, however, prior studies have shown that a majority of mothers 
can correctly recall a child’s birth weight within 100 grams. (34) Prospective studies are 
needed to include this information in risk assessment related to birth weight.
From the beginning of a child’s life, HBW and LBW identify children who have increased 
risk for health-related issues, one being NAFLD. Although abnormal birth weight accounted 
for a minority of children with NAFLD in our study, it was associated with increased risk of 
disease severity. LBW and HBW were associated with the severity of different histologic 
features of NAFLD, thus the underlying mechanism linking LBW or HBW with NAFLD 
may also be different. In conclusion, birth weight involves both maternal and in utero 
factors, which may have long-lasting hepatic consequences.
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Abbreviations
ALT alanine aminotransferase
AST aspartate aminotransferase
BMI body mass index
CI confidence interval
GGT gamma glutamyltransferase
HDL high-density lipoprotein cholesterol
LDL low-density lipoprotein cholesterol
NAFLD nonalcoholic fatty liver disease
NASH nonalcoholic steatohepatitis
NASH CRN Nonalcoholic Steatohepatitis Clinical Research Network
OR odds ratio
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Figure 1. 
The distribution of birth weight in children with NAFLD compared to the general 
population. NAFLD is shown in light grey, and the US population is shown in black. Both 
LBW and HBW are significantly over-represented in children with NAFLD compared the 
general US population, (p value <0.0001).
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Table 3
Adjusted Odds Ratios
Birth Weight Category
Liver Histology Low Normal High
Steatosis Grade 0.93 (0.54, 1.61) 1.00 (ref) 1.82 (1.15, 2.88)
NASH Diagnosis 1.39 (0.71, 2.70) 1.00 (ref) 2.03 (1.21, 3.40)
Advanced Fibrosis 2.23 (1.08, 4.62) 1.00 (ref) 1.43 (0.73, 2.81)
Values shown are adjusted odds ratios and 95% confidence interval. Adjustments were made for age, sex, race/ethnicity, and body mass index.
Bolded OR are significant.
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